Stalicla’s series B adds $17.4M for trials in substance abuse disorders, ASD
Stalicla SA Secures $17.4 Million in Series B Funding to Advance Innovative Therapies Subtitle: Funding Enables Progress in Treating Cocaine Misuse Disorder and Autism Spectrum Disorder Date: Friday, Jan. 19, 2024 Source: BioWorld (©2024 BioWorld. Reprinted with permission from Clarivate.) Stalicla SA Achieves First Close of $17.4 Million Series B Round for Therapeutic Development BioWorld, … Read more